Authors:
Katso, RMT
Manek, S
Ganjavi, H
Biddolph, S
Charnock, MFL
Bradburn, M
Wells, M
Ganesan, TS
Citation: Rmt. Katso et al., Overexpression of H-Ryk in epithelial ovarian cancer: Prognostic significance of receptor expression, CLIN CANC R, 6(8), 2000, pp. 3271-3281
Authors:
Foran, JM
Cunningham, D
Coiffier, B
Solal-Celigny, P
Reyes, F
Ghielmini, M
Johnson, PWM
Gisselbrecht, C
Bradburn, M
Matthews, J
Lister, TA
Citation: Jm. Foran et al., Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response, ANN ONCOL, 11, 2000, pp. 117-121
Authors:
Apostolidis, J
Gupta, RK
Grenzelias, D
Johnson, PWM
Pappa, VI
Summers, KE
Salam, A
Adams, K
Norton, AJ
Amess, JAL
Matthews, J
Bradburn, M
Lister, TA
Rohatiner, AZS
Citation: J. Apostolidis et al., High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up, J CL ONCOL, 18(3), 2000, pp. 527-536
Authors:
Schuh, A
Atoyebi, W
Littlewood, T
Hatton, C
Bradburn, M
Murphy, MF
Citation: A. Schuh et al., Prevention of worsening of severe thrombocytopenia after red cell transfusions by the use of leucocyte-depleted blood, BR J HAEM, 108(2), 2000, pp. 455-457
Authors:
Bishop, JAN
Bradburn, M
Bergman, W
Osterlind, A
Pinney, E
Rosdahl, I
Scerri, L
Weichenthal, M
Mant, D
Breitbart, EW
Karlsson, P
Altman, DG
Citation: Jan. Bishop et al., Teaching non-specialist health care professionals how to identify the atypical mole syndrome phenotype: a multinational study, BR J DERM, 142(2), 2000, pp. 331-337
Authors:
Papamichael, D
Norton, AJ
Foran, JM
Mulatero, C
Mathews, J
Amess, JAL
Bradburn, M
Lister, TA
Rohatiner, AZS
Citation: D. Papamichael et al., Immunocytoma: A retrospective analysis from St Bartholomew's Hospital - 1972 to 1996, J CL ONCOL, 17(9), 1999, pp. 2847-2853
Authors:
Apostolidis, J
Foran, JM
Johnson, PWM
Norton, A
Amess, J
Matthews, J
Bradburn, M
Lister, TA
Rohatiner, AZS
Citation: J. Apostolidis et al., Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma, J CL ONCOL, 17(1), 1999, pp. 216-221